Navigation Links
Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility

(PRWEB) February 08, 2013

Patheon Inc., a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced that it will be hosting a complimentary seminar on “Getting Your Drug Through Phase I Early Development Effectively”. The seminar will be held on Tuesday, February 19th at 11:30 – 6 p.m. Central European Time at Patheon’s Milton Park facility in Oxfordshire, UK.

Patheon recently announced its plans to launch the company’s SoluPath™ program at the Milton Park facility as part of the company’s global strategy to expand early pharmaceutical development services for its customers.

In the upcoming seminar, Patheon have invited three scientific leaders to share their experiences and answer questions on strategies for effectively progressing small molecules through early drug development. Presentations will be provided by Patheon employees, Jon Sutch, Ph.D., and Rick Bastin, as well as from Paul Madeley, Ph.D., with Synth-Isis Ltd. Through case studies and interactive presentations, presenters will discuss early stages of active pharmaceutical ingredient (API) development, formulation strategies and challenges of low solubility and bioavailability. There will also be an opportunity to pose technical questions to the company’s experts through the Ask the Experts round table. Visit Patheon’s website to learn more or register for the upcoming seminar.

About Patheon Inc.

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Through the company’s recent acquisition of Banner Pharmacaps – a market leader in soft gelatin capsule technology – Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. The company's integrated network consists of 18 locations, including 14 commercial contract manufacturing facilities and 12 development centers across North America and Europe. Patheon enables customer products to be launched with confidence anywhere in the world. For more information visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
2. Local Schools Infested With Bed Bugs, Faculty and Victims Receive Complimentary Bed Bug Spray Samples, Explains
3. New No Scrubbing Rust Remover Being Offer As A Complimentary Sample To Save Contractors $1,000, My Cleaning Products Puts The Product To The Test
4. New Ordinance Holds Landlords Responsible To Kill Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Bully To Avoid High Exterminator Fee's
5. Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
6. ComplianceOnline Announces Seminar on Statistical Analysis for Product Development
7. ComplianceOnline Announces Seminar on Clinical Trial Project Supplier Quality Improvement
8. iBioSeminars and iBioMagazine: Free, Online Biology Seminars and Short Talks by Leading Scientists
9. NSG Precision Cells Now Offering a High Grade Flow Through Cell with Unparalled Quality
10. Scientists Describe Breakthrough Technology for Brain Self-Optimization in Newly Published Paper
11. 3D printing breakthrough with human embryonic stem cells
Post Your Comments:
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... The Academy ... Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the ... last few years. Many AMA members have embraced this type of racing and several ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
Breaking Biology Technology:
(Date:11/17/2015)... PARIS , November 17, 2015 ... November 2015.   --> Paris from ... --> DERMALOG, the biometrics innovation leader, has invented the ... and fingerprints on the same scanning surface. Until now two ... fingerprints. Now one scanner can capture both on the same ...
(Date:11/12/2015)... -- A golden retriever that stayed healthy despite having the ... a new lead for treating this muscle-wasting disorder, report ... MIT and Harvard and the University of São Paolo ... Cell, pinpoints a protective gene that boosts muscle ... Boston Children,s lab of Lou Kunkel , PhD, ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):